Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.
|Videos|March 10, 2023
Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC
Author(s)Matthew D. Galsky, MD
Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.
Advertisement
Advertisement
Related to this article
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Natera has submitted Signatera to Japan's PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.
Camrelizumab Plus Nab-Paclitaxel Yields Efficacy in Previously Treated Advanced Urothelial Carcinoma
Later-line camrelizumab plus nab-paclitaxel produced durable responses in platinum-treated advanced urothelial carcinoma.
First-line tislelizumab plus gemcitabine produced durable responses in platinum-ineligible locally advanced or metastatic urothelial carcinoma.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
A Mayo Clinic study found that a new immunotherapy helped patients with aggressive bladder cancer keep their bladder instead of having it removed.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Frequently Asked Questions on the Evolving Management of Early-Stage HER2+ Breast Cancer
4
Study Finds Traditional Prostate Cancer Risk Factors Do Not Predict Hormone Therapy Benefit
5